Different expression patterns of cyclins A, D1 and E in human colorectal cancer

Wang, Aijin; Yoshimi, Naoki; Suzui, Masumi; Yamauchi, Akiji; Tarao, Makoto; Mori, Hideki

doi:10.1007/bf01226270

Cited by 70 publications

(43 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also supports previous reports of deregulated expression and ampli®cation of cyclin D1 in chemically induced skin tumors (Bianchi et al, 1993;Mitsunaga et al, 1995;Robles and Conti, 1995), human tumors (Bartkova et al, 1995a,b;Wang et al, 1996;Weinstat-Saslow et al, 1995) and in rat mammary tumors (Sgambato et al, 1995). Overexpression of cyclin D1 in the mammary glands of transgenic mice leads to hyperplasia and tumor formation (Wang et al, 1994).…”

Section: Discussionsupporting

confidence: 91%

Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin

et al. 1998

View full text Add to dashboard Cite

It is now evident that several genes encoding regulatory activities that control the mammalian cell cycle, particularly some that control the progression of quiescent cells through G1 and into S phase, are targets for alterations that underlie the development of neoplasms. Here, we made a sequential study of alterations in cell cycle protein expression and complex formation among cyclin, cyclin dependent kinases (CDKs) and CDK inhibitors (CKIs) during premalignant progression in SENCAR mouse skin tumors. Changes in the level of expression were observed in positive (cyclin D1, D2, and E2F family members) and negative regulators (p16 Ink4a , p57 Kip2 ) of the cell cycle. Also, we observed the formation of cyclin/CDK/CKI complexes. The amounts of these proteins and complexes increased substantially at speci®c times during promotion but not during malignant conversion to carcinomas. These data show that deregulation of growth control occurs in benign tumors and that subsequent mutations not involved cell-cycle regulation are probably necessary to induce invasive behavior.

show abstract

Section: Discussionsupporting

confidence: 91%

Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Li et al demonstrated that the three-year survival rate of a cyclin E-negative group was significantly lower than that of the cyclin E-positive group (32). The findings of Wang et al support the theory of overexpression of cyclin E in CRC without a significant correlation with clinical and pathological characteristics (33). Bondi et al did not identify a significant correlation between cyclin E expression and gene amplification in primary colon adenocarcinomas and clinical outcome (34).…”

Section: A B Csupporting

confidence: 54%

Expression of cyclin E in stage III colorectal carcinoma

et al. 2012

View full text Add to dashboard Cite

Abstract. Carcinogenesis is characterized by an abnormal regulation of the cell cycle. Regulators of the cell cycle such as cyclin E play an important role in neoplasia and may be correlated with prognosis. The clinical significance of the expression of cyclin E in stage III colorectal carcinoma has not yet been investigated. The expression of cyclin E was evaluated in 49 patients. Using a multivariate analysis, the expression of cyclin E in the tumor at diagnosis was compared with various clinicopathological variables, including age, gender, tumor site, tumor size, tumor differentiation and lymph node involvement. There were more node-positive cases in the cyclin E-negative group than in the cyclin E-positive group (P=0.003). However, there was no correlation between the degree of cyclin E expression and the clinical data. In conclusion, our data suggest that overexpression of cyclin E does not predict the clinical outcome in colorectal cancer stage III. Negative cyclin E staining may be associated with lymph node involvement.

show abstract

“…Overexpression of cD 1 has been reported to negatively influence prognosis in squamous cell carcinomas (SCC) of the larynx (8), but was of no prognostic value in a limited study of NSCLC (16) and mammary carcinomas (17). Increased expression of cE, another key regulatory component of cell cycle control, has been demonstrated in colorectal (18) and mammary carcinomas (19) and has been proposed as a potential and possibly better prognostic marker for breast cancer than cyclin D (19), but its possible role in NSCLC has not been elucidated. Therefore, this study was undertaken to determine the prognostic value of cD 1 and cE in NSCLC.…”

mentioning

confidence: 99%

The Expression of Cyclins D1 and E in Predicting Short-Term Survival in Squamous Cell Carcinoma of the Lung

et al. 2000

View full text Add to dashboard Cite

Cyclins D 1 (cD 1 ) and E (cE) are G 1 phase cyclins believed to participate in the pathogenesis of malignancy. Overexpression of cD 1 has been reported to influence prognosis in squamous cell carcinomas (SCC) of the larynx, but was not significant in a limited study of non-small cell lung cancers (NSCLC). Altered expression of cE has been proposed as another potential prognostic marker in malignancy but its possible role in NSCLC has not been elucidated. In order to determine the prognostic value of cD 1 and cE in NSCLC, paraffinembedded sections of 467 NSCLC were immunostained with monoclonal antibody to cD 1 (1:500, PharMingen, San Diego, CA) and 400 NSCLC with MA to cE (1:2500, PharMingen) using an enhanced sensitivity avidin-biotin complex technique. The number of tumor cells with nuclear and/or cytoplasmic immunopositivity was graded on a scale of: 0 ‫؍‬ less than 1%, 1 ‫؍‬ 1 to 10%, 2 ‫؍‬ 10 to 25%, 3 ‫؍‬ 25 to 50%, 4 ‫؍‬ 50 to 75%, 5 ‫؍‬ more than 75%. Results were correlated with survival by KaplanMeier survival plot using Stat-View software (Abacus Concepts, Berkeley, CA). Overall, 426 NSCLC with cD 1 and 360 NSCLC with cE had adequate follow-up (median, 76 mo) for survival analysis. Both cyclins independently showed significance in prognosis of SCC but not other cell types. For cD 1 , absence of immunostaining was associated with worse prognosis than any immunopositivity for all stages of SCC (P ‫؍‬ .025). For cE, Stage I and II SCC with less than 50% immunopositivity had a worse prognosis (P ‫؍‬ .029). Of 70 Stage I and II SCC immunostained for both monoclonal antibodies, 55% of patients with tumors that demonstrated both absence of cD 1 staining and cE immunopositivity in less than 50% of cells were dead at 5 years compared to 35% of patients with tumors that demonstrated positive staining with cD 1 and cE immunopositivity in more than 50% of cells. These results strongly suggest cD 1 and cE can independently predict prognosis in early stage SCC. Worse prognosis was associated with loss of expression, consistent with mechanisms other than overexpression of these cyclins in the progression of SCC.

show abstract

Different expression patterns of cyclins A, D1 and E in human colorectal cancer

Cited by 70 publications

References 23 publications

Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin

Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin

Expression of cyclin E in stage III colorectal carcinoma

The Expression of Cyclins D1 and E in Predicting Short-Term Survival in Squamous Cell Carcinoma of the Lung

Contact Info

Product

Resources

About